Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug
Once largely overlooked, sickle cell disease (SCD) has recently seen a flurry of approvals. For Pfizer — an SCD drug that has faltered in the pivotal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
